ÂÜŔňÂŇÂ×

Annie Neild joined NewAmsterdam Pharma in March 2021 as Vice President Regulatory Affairs. She has 15 years of experience in the pharmaceutical industry, working across diverse therapeutic areas with small molecules, peptide therapeutics, and biologics. Annie completed her doctoral work at Yale University, where she studied the interactions between intracellular pathogens and the host immune response. After concluding her postdoctoral studies at The Rockefeller University, Annie joined the pharmaceutical industry in 2006. Annie joined the biometrics group at Ironwood Pharmaceuticals in 2010 and was part of the Linzess NDA team before she moved to Regulatory Affairs, where she led the development and submission of IND applications for Ironwood’s soluble guanylate cyclase (sGC) stimulators for cardiovascular and renal indications. She continued her work on these compounds when Cyclerion separated from Ironwood in 2019. Annie joined the Regulatory Affairs team at Corvidia Therapeutics in 2020, where she facilitated the transition of Corvidia’s asset ziltivekimab to Novo Nordisk following the acquisition in July 2020.